Compugen Ltd. (CGEN) Earnings Call Transcripts

Compugen Ltd.'s Latest Earnings Call - June 15, 2026

In the earnings call held on June 15, 2026, Compugen Ltd. (CGEN:US) showcased its unique computational target discovery platform, emphasizing its end-to-end capabilities in immuno-oncology drug development. The company highlighted its successful partnerships with AstraZeneca and Gilead, which have provided substantial milestone potential. While specific revenue and earnings figures were not disclosed, management indicated a strong financial position, allowing for strategic flexibility in clinical programs. Guidance for upcoming clinical data readouts, particularly for COM701 in the MAIA study, is set for Q1 2027, which could significantly impact stock performance depending on the results.

Reported metrics

Guidance from management

Management maintained a positive outlook for the upcoming data readouts and emphasized the importance of clinical validation for their assets. They signaled a focus on strategic partnerships based on program needs rather than a rush to out-license.

What management said

So from our experience, we didn't have any issues because eventually, we are not bringing them the silica package. We're bringing them the experimental package, the preclinical package lots of focus on safety. So the packages that we generated for our computational discovery targets had never any issues with the regulators. We always had a nice path into Phase 1, INDs, acceptance, and all of that. So if you generate...

It's a very competitive space, but there are very few nontoxic agents, which are fighting for that space. And patients after 6 cycles of platinum, some of them may want to have a bit of an easier drug than an ADC, which is eventually toxic. And the pharma companies, which are fighting between themselves with a different ADCs, also on the way to differentiate. So having a combination partner, which is combinable and...

What analysts pressed on

Analysts expressed concerns regarding the high competition in the oncology space and the potential risks associated with clinical trial outcomes. There were questions about how Compugen plans to differentiate its assets in a crowded market and the implications of any setbacks in clinical data.

Main topics on the call

• Unique Computational Platform — Compugen's platform, known as Unigen, is distinguished by its focus on early-stage drug target discovery, which is less competitive than later stages. CEO Eran Ophir stated, "We are focusing on the very first stage of th...
• Clinical Data Readouts — Management confirmed that interim data for the MAIA study of COM701 will be available by Q1 2027, which is critical for assessing the drug's efficacy in ovarian cancer. Ophir noted, "We expect to have the interim analysi...
• Regulatory Confidence — Compugen has experienced no issues with regulators regarding its computationally discovered targets, as they provide robust experimental packages. Ophir stated, "We always had a nice path into Phase 1, INDs, acceptance, ...
• Partnership Strategy — The company is strategically assessing whether to retain full commercialization rights or to out-license assets based on program-specific evaluations. Ophir mentioned, "It's going to be program dependent," indicating a f...

Read the full Compugen Ltd. transcript (June 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 35 Compugen Ltd. earnings call transcripts on record, spanning February 20, 2020 to August 3, 2026. Based on this history, Compugen Ltd. reports quarterly. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CGEN

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

35

First call

February 20, 2020

Most recent

August 3, 2026

Reporting cadence

quarterly